Key result
Each standard deviation increase in baseline TAPSE/PASP ratio reduced the risk of clinical worsening by 60% in patients with chronic thromboembolic pulmonary hypertension (HR 0.402).
Why the study?
Impairment of right ventricle-to-pulmonary artery coupling is a major determinant of poor prognosis in pulmonary hypertension, but its prognostic value in CTEPH using an echo-derived TAPSE/PASP ratio needed evaluation.
Cohort (n=205)
No
May support risk stratification in CTEPH; hypothesis-generating for therapeutic targeting of RV-PA coupling.
Aims: Impairment of right ventricle-to-pulmonary artery coupling (RV-PA coupling) is a major determinant of poor prognosis in patients with pulmonary hypertension. This study sought to evaluate the ability of an echo-derived metric of RV-PA coupling, the ratio between tricuspid annular plane systolic excursion (TAPSE), and pulmonary artery systolic pressure (PASP) and to predict adverse clinical outcomes in chronic thromboembolic pulmonary hypertension (CTEPH). Methods and results: A total of 205 consecutive patients with confirmed CTEPH were retrospectively recruited from Fuwai Hospital between February 2016 and November 2020. Baseline echocardiography, right heart catheterization, and cardiopulmonary exercise testing were analyzed. Patients with lower TAPSE/PASP had a significantly compromised echocardiographic and hemodynamic status and exercise capacity at baseline. The TAPSE/PASP ratio correlated significantly with hemodynamic parameters, including pulmonary vascular resistance ( r = −0.48, p < 0.001) and pulmonary arterial compliance ( r = 0.45, p < 0.001). During a median period of 1-year follow-up, 63 (30.7%) patients experienced clinical worsening. The relationship between TAPSE/PASP and clinical worsening was assessed using different multivariate Cox regression models. After adjustment for a series of previously screened independent predictors, TAPSE/PASP remained significantly associated with outcomes, and the hazard ratio (per standard deviation increase) of the final model was 0.402. Conclusion: In patients with CTEPH, baseline RV-PA coupling measured as the TAPSE/PASP ratio is associated with disease severity and adverse outcomes. A low TAPSE/PASP identifies patients with a high risk of clinical deterioration, and this novel metric could be applicable for risk stratification in CTEPH.
No takes yet. Share an insight, caveat, or question.
Duan et al. (2022) conducted a cohort in Chronic thromboembolic pulmonary hypertension (CTEPH) (n=205). TAPSE/PASP ratio was evaluated on Clinical worsening (death, rehospitalization for HF or deterioration of PH, or escalation of targeted therapy) (HR 0.402, 95% CI 0.239-0.676, p=<0.001). Each standard deviation increase in baseline TAPSE/PASP ratio reduced the risk of clinical worsening by 60% in patients with chronic thromboembolic pulmonary hypertension (HR 0.402).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: